Transforming the Treatment of Cancer & Inflammatory Diseases
See our technology in action
Our Technology
Our unique and proprietary epithelial stem cell cloning platform stemECHO provides unprecedented resolution at the cellular level and has led to the discovery of the underlying mechanism via pathogenic stem cells to cure certain forms of cancer and inflammatory diseases.
Tract has identified drugs that selectively target these pathogenic stem cells in inflammatory airway and intestinal diseases and certain forms of cancer.
Our Mission
Address significant unmet needs by combining disruptive innovation with disciplined execution.
We aspire to enhance the lives of patients suffering from cancer, inflammation and other conditions by changing what’s possible in drug discovery.
Our Strategy
stemECHO is a completely propriety technology that will allow us to clone epithelial stem cells millions of times, all while preserving their genetic integrity.
This is achieved by leveraging the fixed identity of transcription factors-key elements that regulate the function and identity of these stem cells. These transcription factors ensure the stem cells remain undifferentiated as they are replicated so that we grow pure colonies of them.
The result? A uniform population of cells, identical in every respect to the original.
One of the most promising applications is in the treatment of cancers and inflammatory diseases. By maintaining the genetic consistency of the cloned cells, researchers can study disease mechanisms with unprecedented precision. This opens the door to new diagnostic tools and therapies that target the root causes of these conditions.
stemECHO, our groundbreaking technology, allows us to clone and characterize the role of epithelial stem cells in the pathogenesis of inflammation and cancer. These insights will fundamentally change the treatment of certain forms of inflammatory diseases and cancers.
This technology could significantly enhance the future of treatment and prevention, making personalized medicine a standard of care. Tract Bio is pioneering the future of healthcare, transforming our knowledge of epithelial stem cell biology into life-changing therapies. The journey to a healthier world begins at the cellular level.
Explore Our Video Library
Our Team
Our Scientific Founders are pioneers in stem cell biology and disease pathogenesis of epithelial tissue.
Their research has been widely published in peer reviewed top tier journals such as Cell and Nature.
Dr. William Bachovchin, Ph.D.
Scientific Team
Dr. Frank McKeon, Ph.D.
Scientific Team
Dr. Wa Xian, Ph.D.
Scientific Team
Leadership &
Board of Directors
Richard Russell
Chief Executive Officer
Joseph Suarez
Chief Financial Officer
Robert Izard, J.D.
General Counsel
John Noseworthy
Board Member
Ian Banwell
Board Member
Charlie Izard
Board Member
Pipeline
We have created a robust development pipeline based on our unique discoveries and expect to have an IND submitted for Solid Tumors in the next 24 months.
Cancer and Inflammation
We have identified 3 target areas for clinical development of our lead assets. The lead program, TP-101, is targeting solid tumors, including ovarian and breast cancer.
We plan to begin the IND enabling studies on TP-101 for gastric cancer with the goal of gaining approval to begin clinical studies with 24 months. The other programs are focused on additional solid tumors and inflammatory bowel and lung diseases.
